Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PAT Plus Three-Batch Validation Suggested As Transition Approach By FDA

This article was originally published in The Tan Sheet

Executive Summary

Process analytical technologies (PAT) and conventional manufacturing validation methods could be implemented concurrently as a way to avoid product introduction delays during the transition to the new validation approach, FDA suggests

You may also be interested in...



Risk-Based GMPs: FDA Priorities Will Reflect Exposure, Compliance Record

FDA's risk-based inspection model will consider a product's breadth of use when assigning inspection priorities

Risk-Based GMPs: FDA Priorities Will Reflect Exposure, Compliance Record

FDA's risk-based inspection model will consider a product's breadth of use when assigning inspection priorities

Risk-Based GMPs: FDA Priorities Will Reflect Exposure, Compliance Record

FDA's risk-based inspection model will consider a product's breadth of use when assigning inspection priorities

Related Content

Topics

UsernamePublicRestriction

Register

PS093766

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel